MCID: ULC008
MIFTS: 23

Ulcerative Proctitis

Categories: Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Ulcerative Proctitis

MalaCards integrated aliases for Ulcerative Proctitis:

Name: Ulcerative Proctitis 52
Chronic Ulcerative Proctitis 71

Classifications:



External Ids:

ICD10 32 K51.2
UMLS 71 C2937222

Summaries for Ulcerative Proctitis

NIH Rare Diseases : 52 Ulcerative proctitis is a type of ulcerative colitis that affects the rectum. The symptoms of this form of proctitis may include bleeding from the rectum, the need to go to the bathroom frequently, tenesmus , diarrhea or constipation, and rectal pain. People with ulcerative proctitis tend to have episodes when the symptoms worsen and periods without symptoms, although the course of the disease varies among affected individuals. Treatment involves applying 5-aminosalicylic acid (5-ASA) or steroid creams to the rectum. In some cases, an oral version of 5-ASA is used to prevent episodes.

MalaCards based summary : Ulcerative Proctitis, also known as chronic ulcerative proctitis, is related to proctitis and ulcerative colitis. An important gene associated with Ulcerative Proctitis is CRP (C-Reactive Protein). The drugs Tacrolimus and Immunosuppressive Agents have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and prostate.

Related Diseases for Ulcerative Proctitis

Diseases related to Ulcerative Proctitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 37)
# Related Disease Score Top Affiliating Genes
1 proctitis 11.0
2 ulcerative colitis 10.8
3 colitis 10.5
4 inflammatory bowel disease 10.4
5 constipation 10.2
6 chlamydia 10.1
7 systemic lupus erythematosus 10.0
8 pelvic organ prolapse 10.0
9 enterocolitis 10.0
10 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.0
11 gallbladder disease 1 10.0
12 body mass index quantitative trait locus 1 10.0
13 deficiency anemia 10.0
14 severe congenital neutropenia 10.0
15 intestinal pseudo-obstruction 10.0
16 bacterial infectious disease 10.0
17 methemoglobinemia 10.0
18 myiasis 10.0
19 megacolon 10.0
20 neutropenia 10.0
21 diarrhea 10.0
22 lymphogranuloma venereum 10.0
23 lymphadenitis 10.0
24 toxic megacolon 10.0
25 pericarditis 10.0
26 gastritis 10.0
27 hemolytic anemia 10.0
28 appendicitis 10.0
29 intestinal obstruction 10.0
30 crohn's disease 10.0
31 lupus erythematosus 10.0
32 47,xyy 10.0
33 48,xyyy 10.0
34 lymphomatoid papulosis 10.0
35 cytomegalovirus infection 10.0
36 pouchitis 10.0
37 radiation proctitis 10.0

Graphical network of the top 20 diseases related to Ulcerative Proctitis:



Diseases related to Ulcerative Proctitis

Symptoms & Phenotypes for Ulcerative Proctitis

Drugs & Therapeutics for Ulcerative Proctitis

Drugs for Ulcerative Proctitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 23)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
2 Immunosuppressive Agents Phase 4
3 Calcineurin Inhibitors Phase 4
4 Immunologic Factors Phase 4
5
Budesonide Approved Phase 3 51333-22-3 63006 5281004
6 Analgesics, Non-Narcotic Phase 3
7 Mesalamine Phase 3 89-57-6
8 Analgesics Phase 3
9 Antirheumatic Agents Phase 3
10 Anti-Inflammatory Agents Phase 3
11 Anti-Inflammatory Agents, Non-Steroidal Phase 3
12 Respiratory System Agents Phase 3
13 Hormones Phase 3
14 Anti-Asthmatic Agents Phase 3
15 Hormone Antagonists Phase 3
16 glucocorticoids Phase 3
17 Bronchodilator Agents Phase 3
18 Cola Phase 3
19
Niclosamide Approved, Investigational, Vet_approved Phase 1, Phase 2 50-65-7 4477
20 Anti-Infective Agents Phase 1, Phase 2
21 Antiparasitic Agents Phase 1, Phase 2
22 Anthelmintics Phase 1, Phase 2
23 Acidophilus Phase 2

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 A Multi-centre Double Blind Randomised Placebo-controlled Study of the Use of Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo
2 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam (2 mg/25 mL BID for 2 Weeks, Followed by 2 mg/25 mL QD for 4 Weeks) Versus Placebo in Subjects With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis Completed NCT01008423 Phase 3 Budesonide;Placebo
3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam (2 mg/25 mL BID for 2 Weeks, Followed by 2 mg/25 mL QD for 4 Weeks) Versus Placebo in Subjects With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis Completed NCT01008410 Phase 3 Budesonide;Placebo
4 AN INVESTIGATOR-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ESTABLISH THERAPEUTIC EQUIVALENCE OF 1000 mg MESALAMINE RECTAL SUPPOSITORIES AND CANASA® RECTAL SUPPOSITORIES (1000 mg MESALAMINE, USP) IN THE TREATMENT OF MILD TO MODERATE ULCERATIVE PROCTITIS Terminated NCT01172444 Phase 3 Mesalamine;Canasa;Placebo
5 A Phase 3, Open Label, Multicenter Study to Assess the Safety and Tolerability of Budesonide Foam in Subjects With Active Ulcerative Proctitis or Proctosigmoiditis Terminated NCT01349673 Phase 3 Budesonide Foam
6 A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis Terminated NCT01016262 Phase 3 MAX-002;Placebo;Canasa®
7 Randomized, Double-blind, Multicentre Study to Compare the Efficacy and Safety of Budesonide Versus Mesalazine Suppository Versus a Combination Therapy of Budesonide/Mesalazine Suppositories in Patients With Acute Ulcerative Proctitis Completed NCT01966783 Phase 2 Budesonide 2 mg suppository;Budesonide 4 mg suppository;Mesalazine 1 g suppository;Budesonide 2 mg suppository/Mesalazine 1 g suppository
8 Assessment of the Photopill Capsule Treatment for Safety and Feasibility in Patients With Ulcerative Proctitis Completed NCT01837615 Phase 2
9 A Phase I/IIA, Open-Label, Three-Stage Study to Investigate the Safety, the Efficacy and the Pharmacokinetics of Niclosamide Enemas in Subjects With Active Ulcerative Proctitis or Ulcerative Procto-Sigmoiditis Recruiting NCT03521232 Phase 1, Phase 2 Niclosamide
10 The Effect of Lactobacillus Reuteri ATCC PTA 4659 in Patients With Ulcerative Colitis Recruiting NCT03798210 Phase 2
11 QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®) Completed NCT02368743 mesalazine
12 Autonomic and Cytokines Profiles of Patients With Ulcerative Proctitis Recruiting NCT03259659

Search NIH Clinical Center for Ulcerative Proctitis

Genetic Tests for Ulcerative Proctitis

Anatomical Context for Ulcerative Proctitis

MalaCards organs/tissues related to Ulcerative Proctitis:

40
Colon, Liver, Prostate, Monocytes, T Cells, Pituitary

Publications for Ulcerative Proctitis

Articles related to Ulcerative Proctitis:

(show top 50) (show all 244)
# Title Authors PMID Year
1
No Superiority of Tacrolimus Suppositories vs Beclomethasone Suppositories in a Randomized Trial of Patients With Refractory Ulcerative Proctitis. 61
31610337 2020
2
Ulcerative Proctitis in a Patient With a History of Fecal Microbiota Transplant for Clostridioides difficile Infection. 61
32548192 2020
3
Correlation between biomarkers (calprotectin, seromucoid, metalloproteinase-3 and CRP) and clinical and endoscopic activity of ulcerative colitis in children. 61
32361483 2020
4
Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. 61
31202984 2020
5
Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases. 61
32100944 2020
6
Time to include patients with ulcerative proctitis in clinical trials. 61
31696821 2019
7
A positive clinical experience of a long-term treatment pattern with leukocyte apheresis and Adacolumn in ulcerative proctitis. 61
31595764 2019
8
Chlamydia trachomatis: when the virulence-associated genome backbone imports a prevalence-associated major antigen signature. 61
31697227 2019
9
Rectal Lymphoid Follicle Aphthous Lesions Frequently Progress to Ulcerative Colitis with Proximal Extension. 61
30333412 2019
10
Tacrolimus Suppositories in Therapy-Resistant Ulcerative Proctitis. 61
30820433 2019
11
Acetarsol in the management of mesalazine-refractory ulcerative proctitis: a tertiary-level care experience. 61
30499784 2019
12
Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis. 61
29702300 2019
13
Topical mesalazine as a cause of Stevens-Johnson syndrome. 61
29931986 2018
14
Inflammatory Bowel Disease Across the Age Continuum: Similarity and Disparity. 61
29572605 2018
15
Endoscopic progression of ulcerative proctitis to proximal disease. Can we identify predictors of progression? 61
30351984 2018
16
Linear IgA bullous dermatosis associated with ulcerative proctitis: treatment challenge. 61
30261573 2018
17
Efficacy of topical 5-aminosalicylate monotherapy in patients with ulcerative proctitis with skip inflammation. 61
29205498 2018
18
The treatment of refractory ulcerative colitis. 61
30060939 2018
19
Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis. 61
29207381 2018
20
Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository. 61
29393142 2018
21
Multi Matrix System Mesalazine Plus Rectal Mesalazine in the Treatment of Mild to Moderately Active Ulcerative Proctitis. 61
29339645 2018
22
The role of confocal laser endomicroscopy in assessing mucosal healing in patients with ulcerative proctitis. 61
29186737 2017
23
Therapeutic requirements in active ulcerative proctitis: A single-centre study. 61
28666605 2017
24
Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. 61
27489240 2017
25
Clinical Predictors and Natural History of Disease Extension in Patients with Ulcerative Proctitis. 61
28922252 2017
26
Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis. 61
28724302 2017
27
Colorectal Cancer and Precancerous Lesions Associated with Ulcerative Colitis in Thailand 61
28843232 2017
28
Revision of the demographic and clinical data of patients with ulcerative colitis in Turkey. 61
28786968 2017
29
Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis. 61
28286194 2017
30
Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study. 61
28089625 2017
31
Infliximab-Induced Lupus: A Case Report. 61
29255743 2017
32
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. 61
27416045 2016
33
Controversies in Pouch Surveillance for Patients with Inflammatory Bowel Disease. 61
26822612 2016
34
Clinical pattern and progression of ulcerative proctitis in the Japanese population: a retrospective study of incidence and risk factors influencing progression. 61
26663677 2016
35
Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications. 61
27446860 2016
36
A case of appendectomy as main therapeutic intervention for complex co-morbid ulcerative proctitis. 61
25690705 2015
37
Improvement of Refractory Ulcerative Proctitis With Sacral Nerve Stimulation. 61
25930972 2015
38
Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. 61
26386854 2015
39
Oral 5-aminosalicylate, mesalamine suppository and mesalamine enema as initial therapy for ulcerative proctitis in clinical practice with quality of care implications. 61
26469062 2015
40
Systematic Review: Rectal Therapies for the Treatment of Distal Forms of Ulcerative Colitis. 61
26020604 2015
41
Deep comparative genomics among Chlamydia trachomatis lymphogranuloma venereum isolates highlights genes potentially involved in pathoadaptation. 61
25745888 2015
42
[Budesonide foam for ulcerative proctitis and proctosigmoiditis]. 61
25991492 2015
43
Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. 61
25644096 2015
44
Pathogenesis, diagnosis, and management of ulcerative proctitis, chronic radiation proctopathy, and diversion proctitis. 61
25687266 2015
45
Use of intravitreal triamcinolone for the treatment of optic nerve edema in a patient with acute retinal necrosis: case report. 61
25383844 2015
46
Drug therapies for ulcerative proctitis: systematic review and meta-analysis. 61
25072502 2014
47
Ulcerative proctitis in out-patient practice: an unexpected clinical challenge. 61
25176055 2014
48
Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China. 61
24828856 2014
49
Ulcerative proctitis: an update on the pharmacotherapy and management. 61
24837209 2014
50
Successful treatment for ulcerative proctitis with rectal tacrolimus in an 8-year-old girl with intolerance to mesalamine. 61
26185880 2014

Variations for Ulcerative Proctitis

Expression for Ulcerative Proctitis

Search GEO for disease gene expression data for Ulcerative Proctitis.

Pathways for Ulcerative Proctitis

GO Terms for Ulcerative Proctitis

Sources for Ulcerative Proctitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....